Cytosine modifications in myeloid malignancies

Kristen M. Meldi, Maria Figueroa

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aberrant DNA methylation is a hallmark of many cancers, including the myeloid malignancies acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The discovery of TET-mediated demethylation of 5-methylcytosine (5mC) and technological advancements in next-generation sequencing have permitted the examination of other cytosine modifications, namely 5-hydroxymethylcytosine (5hmC), in these myeloid malignancies on a genome-wide scale. Due to the prominence of mutations in epigenetic modifiers that can influence cytosine modifications in these disorders, including IDH1/2, TET2, and DNMT3A, many recent studies have evaluated the relative levels, distribution, and functional consequences of cytosine modifications in leukemic cells. Furthermore, several therapies are being used to treat AML and MDS that target various proteins within the cytosine modification pathway in an effort to revert the abnormal epigenetic patterns that contribute to the diseases. In this review, we provide an overview of cytosine modifications and selected technologies currently used to distinguish and analyze these epigenetic marks in the genome. Then, we discuss the role of mutant enzymes, including DNMT3A, TET2, IDH1/2, and the transcription factor, WT1, in disrupting normal patterns of 5mC and 5hmC in AML and MDS. Finally, we describe several therapies, both standard, front-line treatments and new drugs in clinical trials, aimed at inhibiting the proteins that ultimately lead to aberrant cytosine modifications in these diseases.

Original languageEnglish (US)
Pages (from-to)42-53
Number of pages12
JournalPharmacology and Therapeutics
Volume152
DOIs
StatePublished - Jun 29 2015
Externally publishedYes

Fingerprint

Cytosine
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Epigenomics
5-Methylcytosine
Neoplasms
Genome
DNA Methylation
Proteins
Transcription Factors
Clinical Trials
Technology
Mutation
Enzymes
Therapeutics
Pharmaceutical Preparations

Keywords

  • Acute myeloid leukemia
  • DNA methylation
  • DNA methyltransferase inhibitors
  • Hydroxymethylation
  • Myelodysplastic syndromes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Cytosine modifications in myeloid malignancies. / Meldi, Kristen M.; Figueroa, Maria.

In: Pharmacology and Therapeutics, Vol. 152, 29.06.2015, p. 42-53.

Research output: Contribution to journalArticle

@article{fcdcad56589d47deb6cf9e65f877d175,
title = "Cytosine modifications in myeloid malignancies",
abstract = "Aberrant DNA methylation is a hallmark of many cancers, including the myeloid malignancies acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The discovery of TET-mediated demethylation of 5-methylcytosine (5mC) and technological advancements in next-generation sequencing have permitted the examination of other cytosine modifications, namely 5-hydroxymethylcytosine (5hmC), in these myeloid malignancies on a genome-wide scale. Due to the prominence of mutations in epigenetic modifiers that can influence cytosine modifications in these disorders, including IDH1/2, TET2, and DNMT3A, many recent studies have evaluated the relative levels, distribution, and functional consequences of cytosine modifications in leukemic cells. Furthermore, several therapies are being used to treat AML and MDS that target various proteins within the cytosine modification pathway in an effort to revert the abnormal epigenetic patterns that contribute to the diseases. In this review, we provide an overview of cytosine modifications and selected technologies currently used to distinguish and analyze these epigenetic marks in the genome. Then, we discuss the role of mutant enzymes, including DNMT3A, TET2, IDH1/2, and the transcription factor, WT1, in disrupting normal patterns of 5mC and 5hmC in AML and MDS. Finally, we describe several therapies, both standard, front-line treatments and new drugs in clinical trials, aimed at inhibiting the proteins that ultimately lead to aberrant cytosine modifications in these diseases.",
keywords = "Acute myeloid leukemia, DNA methylation, DNA methyltransferase inhibitors, Hydroxymethylation, Myelodysplastic syndromes",
author = "Meldi, {Kristen M.} and Maria Figueroa",
year = "2015",
month = "6",
day = "29",
doi = "10.1016/j.pharmthera.2015.05.002",
language = "English (US)",
volume = "152",
pages = "42--53",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Cytosine modifications in myeloid malignancies

AU - Meldi, Kristen M.

AU - Figueroa, Maria

PY - 2015/6/29

Y1 - 2015/6/29

N2 - Aberrant DNA methylation is a hallmark of many cancers, including the myeloid malignancies acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The discovery of TET-mediated demethylation of 5-methylcytosine (5mC) and technological advancements in next-generation sequencing have permitted the examination of other cytosine modifications, namely 5-hydroxymethylcytosine (5hmC), in these myeloid malignancies on a genome-wide scale. Due to the prominence of mutations in epigenetic modifiers that can influence cytosine modifications in these disorders, including IDH1/2, TET2, and DNMT3A, many recent studies have evaluated the relative levels, distribution, and functional consequences of cytosine modifications in leukemic cells. Furthermore, several therapies are being used to treat AML and MDS that target various proteins within the cytosine modification pathway in an effort to revert the abnormal epigenetic patterns that contribute to the diseases. In this review, we provide an overview of cytosine modifications and selected technologies currently used to distinguish and analyze these epigenetic marks in the genome. Then, we discuss the role of mutant enzymes, including DNMT3A, TET2, IDH1/2, and the transcription factor, WT1, in disrupting normal patterns of 5mC and 5hmC in AML and MDS. Finally, we describe several therapies, both standard, front-line treatments and new drugs in clinical trials, aimed at inhibiting the proteins that ultimately lead to aberrant cytosine modifications in these diseases.

AB - Aberrant DNA methylation is a hallmark of many cancers, including the myeloid malignancies acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The discovery of TET-mediated demethylation of 5-methylcytosine (5mC) and technological advancements in next-generation sequencing have permitted the examination of other cytosine modifications, namely 5-hydroxymethylcytosine (5hmC), in these myeloid malignancies on a genome-wide scale. Due to the prominence of mutations in epigenetic modifiers that can influence cytosine modifications in these disorders, including IDH1/2, TET2, and DNMT3A, many recent studies have evaluated the relative levels, distribution, and functional consequences of cytosine modifications in leukemic cells. Furthermore, several therapies are being used to treat AML and MDS that target various proteins within the cytosine modification pathway in an effort to revert the abnormal epigenetic patterns that contribute to the diseases. In this review, we provide an overview of cytosine modifications and selected technologies currently used to distinguish and analyze these epigenetic marks in the genome. Then, we discuss the role of mutant enzymes, including DNMT3A, TET2, IDH1/2, and the transcription factor, WT1, in disrupting normal patterns of 5mC and 5hmC in AML and MDS. Finally, we describe several therapies, both standard, front-line treatments and new drugs in clinical trials, aimed at inhibiting the proteins that ultimately lead to aberrant cytosine modifications in these diseases.

KW - Acute myeloid leukemia

KW - DNA methylation

KW - DNA methyltransferase inhibitors

KW - Hydroxymethylation

KW - Myelodysplastic syndromes

UR - http://www.scopus.com/inward/record.url?scp=84933674342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933674342&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2015.05.002

DO - 10.1016/j.pharmthera.2015.05.002

M3 - Article

C2 - 25956466

AN - SCOPUS:84933674342

VL - 152

SP - 42

EP - 53

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

ER -